FrancophonIA/ELRC3.0 huggingface dataset:
English: 1 transdermal patch of 10 cm contains 18 mg rivastigmine and delivers 9.5 mg/24 h.
Estonian: Üks 10 cm transdermaalne plaaster sisaldab 18 mg rivastigmiini ja vabastab 9,5 mg/24 h.
English: Prometax 2 mg/ml [folding box only]
Estonian: Prometax 2 mg/ml [ainult pappkarbil]
English: Take off the previous patch before putting ONE new patch on.
Estonian: Eemaldage eelmine plaaster enne ÜHE uue plaastri asetamist.
English: Transdermal patch Novartis Pharma GmbH Roonstraße 25
Estonian: Transdermaalne plaaster Novartis Pharma GmbH Roonstraße 25
English: Patients involved in the active comparator controlled study had an initial baseline MMSE score of 10-24.
Estonian: Võrdlusravimiga uuringus osalevatel patsientidel oli algtaseme MMSE skoor 10...24.
English: • Hepatic impairment: Due to increased exposure in mild to moderate hepatic impairment as observed with the oral formulation, dosing recommendations to titrate according to individual tolerability should be closely followed.
Estonian: • Maksakahjustus: Täpselt tuleb järgida annuse suurendamise juhiseid ja arvestada ravimi individuaalset talutavust, kuna nagu on nähtud suukaudse ravimvormi puhul, suureneb kerge kuni mõõduka maksakahjustuse korral ravimi sisaldus plasmas.
English: How to take Prometax
Estonian: Kuidas Prometax'i võtta
English: • The signs of Parkinson's disease get worse - such as tremor, stiffness and shuffling
Estonian: • Parkinsoni tõve nähtude süvenemine - treemor, jäikus ja põiklev kõne
English: Pruritus, allergic dermatitis (disseminated) General disorders and administration site conditions Common
Estonian: Kihelus, allergiline dermatiit (dissemineeritud) Üldised häired ja manustamiskoha reaktsioonid Sage
English: Baseline 264 34.4 268 34.9 DB-week 48 Value
Estonian: TP-nädal 48 Väärtus 264 38,5 268 39,7 Muutus
English: Skin application site reactions
Estonian: Manustamiskoha reaktsioonid nahal
English: ADCSCGIC Prometax
Estonian: ADCS-CGIC Prometax
English: Each Prometax 4.5 mg capsule contains 4.5 mg of rivastigmine.
Estonian: Üks Prometax 4,5 mg kapsel sisaldab 4,5 mg rivastigmiini.
English: Rivastigmine might interfere with the activity of anticholinergic medicinal products (e.g oxybutynin, tolterodine).
Estonian: Rivastigmiin võib mõjutada antikolinergiliste ravimpreparaatide(nt oksübutüniin, tolterodiin) aktiivsust.
English: • Inflammation of the pancreas - the signs include serious upper stomach pain, often with feeling sick (nausea) or being sick (vomiting)
Estonian: • kõhunäärme põletik - sümptomiteks on tugev ülakõhuvalu, halb enesetunne (iiveldus) või haigus (oksendamine)
English: Prometax 13.3 mg/24 h transdermal patches: Each patch releasing 13.3 mg of rivastigmine per 24 hours is 15 cm and contains 27 mg of rivastigmine.
Estonian: Prometax 13,3 mg/24 h transdermaalsed plaastrid: Üks plaaster vabastab 24 tunni jooksul 13,3 mg rivastigmiini ning 15 cm plaaster sisaldab 27 mg rivastigmiini.
English: • Uneven heart rate (e.g. fast heart rate)
Estonian: • südame rütmihäired (näiteks kiire südamerütm)
English: What Prometax contains - The active substance is rivastigmine hydrogen tartrate.
Estonian: Mida Prometax sisaldab - Toimeaine on rivastigmiinvesiniktartraat.
English: The active substance of Prometax is rivastigmine.
Estonian: Prometax'i toimeaine on rivastigmiin.
English: - Prometax 9.5 mg/24 h transdermal patches: Each patch releasing 9.5 mg of rivastigmine per 24 hours is 10 cm and contains 18 mg of rivastigmine.
Estonian: Prometax 9,5 mg/24 h transdermaalsed plaastrid: Üks plaaster vabastab 24 tunni jooksul 9,5 mg rivastigmiini ning 10 cm plaaster sisaldab 18 mg rivastigmiini.
English: Hallucination, visual
Estonian: Nägemishallutsinatsioonid
English: Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours.
Estonian: Ühest transdermaalsest plaastrist vabaneb 24 tunni jooksul 4,6 mg rivastigmiini.
English: Application site skin reactions (usually mild to moderate application site erythema), are the most frequent adverse reactions observed with the use of Prometax transdermal patch.
Estonian: Prometax'i transdermaalse plaastrite kasutamisel kõige sagedamini esinenud kõrvaltoimeted on nahareaktsioonid manustamiskohal (tavaliselt manustamiskoha kerge kuni mõõdukas punetus).
English: - Prometax 4.6 mg/24 h transdermal patches: Each patch releasing 4.6 mg of rivastigmine per 24 hours is 5 cm and contains 9 mg of rivastigmine.
Estonian: Prometax 4,6 mg/24 h transdermaalsed plaastrid: Üks plaaster vabastab 24 tunni jooksul 4,6 mg rivastigmiini ning 5 cm plaaster sisaldab 9 mg rivastigmiini.
English: Aggression, restlessness
Estonian: Agressioon, rahutus
English: The outside of the backing layer is beige and labelled with “Prometax”, “13.3 mg/24 h” and “CNFU”.
Estonian: Plaastri tagakülg on beež ja märgistusega “Prometax”, “13.3 mg/24 h” ja “CNFU”.
English: - A protective liner covers the sticky side of the patch.
Estonian: Plaastri kleepuvat poolt katab kaitsekile.
English: Prometax 4.6 mg/24 h transdermal patch Prometax 9.5 mg/24 h transdermal patch Prometax 13.3 mg/24 h transdermal patch rivastigmine
Estonian: Prometax 4,6 mg/24 h transdermaalne plaaster Prometax 9,5 mg/24 h transdermaalne plaaster Prometax 13,3 mg/24 h transdermaalne plaaster rivastigmiin (Rivastigminum)
English: Prometax 4.6 mg/24 h transdermal patch Prometax 9.5 mg/24 h transdermal patch Prometax 13.3 mg/24 h transdermal patch
Estonian: Prometax 4,6 mg/24 h transdermaalne plaaster Prometax 9,5 mg/24 h transdermaalne plaaster Prometax 13,3 mg/24 h transdermaalne plaaster
English: Each Prometax 3.0 mg capsule contains 3.0 mg of rivastigmine.
Estonian: Üks Prometax 3,0 mg kapsel sisaldab 3,0 mg rivastigmiini.
English: • Keep the transdermal patch in the sachet until use.
Estonian: • Kuni kasutamiseni hoida plaaster kotikeses.
English: The outside of the backing layer is beige and labelled with “Prometax”, “9.5 mg/24 h” and “BHDI”.
Estonian: Plaastri tagakülg on beež ja märgistusega “Prometax”, “9.5 mg/24 h” ja “BHDI”.
English: What Prometax is and what it is used for What you need to know before you use Prometax How to use Prometax
Estonian: Mis ravim on Prometax ja milleks seda kasutatakse Mida on vaja teada enne Prometax'i kasutamist Kuidas Prometax'i kasutada Võimalikud kõrvaltoimed Kuidas Prometax'i säilitada Pakendi sisu ja muu teave
English: Each transdermal patch of 10 cm contains 18 mg of rivastigmine.
Estonian: Üks 10 cm transdermaalne plaaster sisaldab 18 mg rivastigmiini (Rivastigminum).
English: No specific interaction studies have been performed with Prometax transdermal patches.
Estonian: Prometax transdermaalsete plaastritega ei ole spetsiifilisi koostoimeid uuritud.
English: One of the excipients in Prometax oral solution is sodium benzoate.
Estonian: Prometax suukaudse lahuse üheks abiaineks on naatriumbensoaat.
English: • A patient on a dose of 12 mg/day oral rivastigmine can be switched to 9.5 mg/24 h transdermal patches.
Estonian: • Patsiendi, kes saab suukaudset rivastigmiini annuses 12 mg ööpäevas, võib üle viia 9,5 mg/24 h transdermaalsete plaastrite kasutamisele.
English: Each transdermal patch of 15 cm contains 27 mg of rivastigmine.
Estonian: Üks 15 cm transdermaalne plaaster sisaldab 27 mg rivastigmiini (Rivastigminum).
English: These include the ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, a performance-based measure of cognition) and the ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinician's Global Impression of Change, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the ADCS-ADL (Alzheimer's Disease Cooperative StudyActivities of Daily Living, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities related to finances).
Estonian: Nendeks olid ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, kognitiivse funktsiooni hindamine sooritusvõime järgi), ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinician's Global Impression of Change, patsiendile laiahaardelise üldhinnangu andmine arsti poolt, hõlmab ka hooldajalt saadud andmeid) ja ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living, hooldajapoolne hinnang igapäevategevustele, sealhulgas isiklik hügieen, söömine, riietumine, kodutööd, poes käimine, orienteerumisvõime, rahaga seotud tegevused jne).
English: There is no relevant use of Prometax in the paediatric population in the treatment of Alzheimer's disease.
Estonian: Puudub Prometax'i asjakohane kasutus lastel Alzheimeri tõve ravis.
English: - if you have impaired liver function.
Estonian: - kui teil esinevad maksatalitluse häired.
English: Prometax is used for the treatment of adult patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Estonian: See on süvenev ajuhäire, mis järk-järgult mõjutab mälu, intellektuaalset võimekust ja käitumist.
English: Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours.
Estonian: Ühest transdermaalsest plaastrist vabaneb 24 tunni jooksul 9,5 mg rivastigmiini.
English: EXP Use Prometax oral solution within 1 month of opening the bottle.
Estonian: Kõlblik kuni: Prometax suukaudset lahust võib kasutada ühe kuu jooksul pärast pudeli avamist.
English: Nightmares
Estonian: Luupainajad
English: No pharmacokinetic interaction was observed between oral rivastigmine and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers.
Estonian: Uuringutes osalenud tervetel vabatahtlikel ei ole täheldatud farmakokineetilisi koostoimeid rivastigmiini ning digoksiini, varfariini, diasepaami või fluoksetiini vahel.
English: Also contains: polyethylene terephthalate film lacquered, alpha-tocopherol, poly(butylmethacrylate, methylmethacrylate), acrylic copolymer, silicone oil, dimethicone, polyester film fluoropolymercoated.
Estonian: Sisaldab ka: lakitud polüetüleentreftalaatkile, alfa-tokoferool, polü(butüülmetakrülaat, metüülmetakrülaat), akrüülkopolümeer, silikoonõli, dimetikoon, fluoropolümeeriga kaetud polüesterkile.
English: Each transdermal patch of 5 cm contains 9 mg of rivastigmine.
Estonian: Üks 5 cm transdermaalne plaaster sisaldab 9 mg rivastigmiini (Rivastigminum).
English: What Prometax looks like and contents of the pack - Prometax 1.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a yellow cap and yellow body, with red imprint “ENA 713 1,5 mg” on the body.
Estonian: Kuidas Prometax välja näeb ja pakendi sisu - Prometax 1,5 mg kõvakapslid sisaldavad kollakasvalget kuni helekollast värvi pulbrit.
English: The incidence of application site skin reactions leading to discontinuation was ≤2.3% in patients treated with Prometax transdermal patches.
Estonian: Prometax transdermaalsete plaastritega ravi saanud patsientidel oli katkestamise määr manustamiskoha nahareaktsioonide tõttu ≤2,3%.
English: Bradycardia
Estonian: Stenokardia
English: Keep the transdermal patch in the sachet until use.
Estonian: Kuni kasutamiseni hoida transdermaalne plaaster kotikeses.
English: Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10-24.
Estonian: Uuringus osalesid patsiendid, kelle MMSE (Mini-Mental State Examination) skoor oli 10...24.
English: Mean change at week 24  SD -0.6  6.4 p-value versus placebo
Estonian: Keskmine algtase ± SH Keskmine muutus 24 nädalal ± SH Kohandatud ravierinevus p-väärtus vs platseebo
English: - The other ingredients are polyethylene terephthalate film lacquered, alpha-tocopherol, poly(butylmethacrylate, methylmethacrylate), acrylic copolymer, silicone oil, dimethicone, polyester film fluoropolymer-coated.
Estonian: - Teised koostisosad on: lakitud polüetüleentereftalaatkile, alfa-tokoferool, polü(butüülmetakrülaat, metüülmetakrülaat), akrüülkopolümeer, silikoonõli, dimetikoon, fluoropolümeeriga kaetud polüesterkile.
English: Each transdermal patch releases 13.3 mg of rivastigmine per 24 hours.
Estonian: Ühest transdermaalsest plaastrist vabaneb 24 tunni jooksul 13,3 mg rivastigmiini.
English: • A patient on a dose of 3 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches.
Estonian: • Patsiendi, kes saab suukaudset rivastigmiini annuses 3 mg ööpäevas, võib üle viia 4,6 mg/24 h transdermaalsete plaastrite kasutamisele.
English: The oral solution is packaged with an oral dosing syringe in a plastic tube container.
Estonian: Suukaudne lahus on pakendis koos plastmassist kaitsekestas oleva annustamissüstlaga.
English: Caution when Prometax is taken together with beta-blockers (medicines such as atenolol used to treat hypertension, angina and other heart conditions).
Estonian: Ettevaatust Prometax'i kasutamisel koos beetablokaatoritega (ravimid, nagu atenolool, millega ravitakse kõrget vererõhku, rinnaangiini ja teisi südamehaigusi).
English: Poly(butylmethacrylate, methylmethacrylate) Acrylic copolymer
Estonian: Polü(butüülmetakrülaat, metüülmetakrülaat) Akrüülkopolümeer
English: Prometax 2 mg/ml oral solution rivastigmine
Estonian: Prometax 2 mg/ml suukaudne lahus Rivastigminum
English: Caution when Prometax Patch is given together with beta-blockers (medicines such as atenolol used to treat hypertension, angina, and other heart conditions).
Estonian: Ettevaatust Prometax plaastri kasutamisel koos beetablokaatoritega (ravimid, nagu atenolool, millega ravitakse kõrget vererõhku, rinnaangiini ja teisi südamehaigusi).
English: Baseline 265 27.5 271 25.8 Week 48 Value
Estonian: Nädal 48 Väärtus 265 23,1 271 19,6 Muutus
English: • A patient on a dose of 6 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches.
Estonian: • Patsiendi, kes saab suukaudset rivastigmiini annuses 6 mg ööpäevas, võib üle viia 4,6 mg/24 h transdermaalsete plaastrite kasutamisele.
English: Each ml contains rivastigmine hydrogen tartrate corresponding to 2 mg rivastigmine.
Estonian: Üks ml lahust sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 2 mg rivastigmiinile (Rivastigminum).
English: • Changes in tests which show how well the liver is working
Estonian: • maksa funktsionaalsete testide näitajate muutus
English: Urinary incontinence General disorders and administration site conditions Common
Estonian: Uriinipidamatus Üldised häired ja manustamiskoha reaktsioonid Sage
English: This may indicate a potential for Prometax transdermal patches to induce mild erythema in patients.
Estonian: See võib viidata Prometax transdermaalsete plaastrite võimalikule kerget erüteemi põhjustavale toimele.
English: The increase in prothrombin time induced by warfarin is not affected by administration of oral rivastigmine.
Estonian: Rivastigmiini manustamine ei mõjuta varfariini toimel pikenenud protrombiini aega.
English: 1 transdermal patch per sachet
Estonian: 1 transdermaalne plaaster kotikeses
English: 30 transdermal patches.
Estonian: 30 transdermaalset plaastrit, multipakendi komponent.
English: Malaise
Estonian: Rahutus
English: The results for clinically relevant responders from the 24-week placebo-controlled study are provided in Table 3.
Estonian: Kliiniliselt olulise vastusreaktsiooniga patsientide kohta kogutud andmed on toodud tabelis 4.
English: Gait disturbance
Estonian: Häiritud liigutused
English: How to store Prometax
Estonian: Kuidas Prometax'i säilitada
English: Prometax transdermal patches 9.5 mg/24 h
Estonian: Prometax transdermaalsed plaastrid 9,5 mg/24 h
English: 1 capsule contains 1.5 mg rivastigmine present as rivastigmine hydrogen tartrate.
Estonian: 1 kapsel sisaldab 1,5 mg rivastigmiini rivastigmiinvesiniktartraadina.
English: Efficacy was established by the use of ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, a performance-based measure of cognition) and the ADCS-IADL (Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living) assessing instrumental activities which include maintaining finances, meal preparation, shopping, ability to orient oneself to surroundings, ability to be left unattended.
Estonian: Efektiivsuse tagamiseks kasutati ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, kognitiivse funktsiooni hindamine sooritusvõime järgi) ja ADCS-IADL (Alzheimer's Disease Cooperative StudyInstrumental Activities of Daily Living).
English: Adhesive matrix
Estonian: Adhesiivne kiht
English: • Feeling agitated
Estonian: • rahutuse tunne
English: You should only open the sachet when you are ready to apply the patch.
Estonian: Avage kotike alles vahetult enne plaastri kasutamist.
English: Application site skin reactions (e.g. application site erythema*, application site pruritus*, application site oedema*, application site dermatitis, application site irritation), asthenic conditions (e.g. fatigue, asthenia), pyrexia, weight decreased
Estonian: Manustamiskoha nahareaktsioonid (nt manustamiskoha punetus*, sügelus*, turse*, nahapõletik manustamiskohas, ärritusnähud manustamiskohas), asteenilised seisundid (nt väsimus, asteenia), palavik, kaalulangus
English: Prometax 6.0 mg hard capsules rivastigmine
Estonian: Prometax 6,0 mg kõvakapslid Rivastigminum
English: • to patients with sick sinus syndrome or conduction defects (sino-atrial block, atrio-ventricular block) (see section 4.8);
Estonian: • patsientidele, kellel on siinussõlme nõrkuse sündroom või juhtehäired (sinuatriaalne blokaad,
English: Prometax 4.5 mg hard capsules rivastigmine
Estonian: Prometax 4,5 mg kõvakapslid Rivastigminum
English: 1 capsule contains 6.0 mg rivastigmine present as rivastigmine hydrogen tartrate.
Estonian: 1 kapsel sisaldab 6,0 mg rivastigmiini rivastigmiinvesiniktartraadina.
English: Each ml contains 2 mg rivastigmine present as rivastigmine hydrogen tartrate.
Estonian: Üks ml lahust sisaldab 2 mg rivastigmiini rivastigmiinvesiniktartraadina.
English: Each capsule contains rivastigmine hydrogen tartrate corresponding to 6.0 mg rivastigmine.
Estonian: Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 6,0 mg rivastigmiinile (Rivastigminum).
English: 1 capsule contains 4.5 mg rivastigmine present as rivastigmine hydrogen tartrate.
Estonian: 1 kapsel sisaldab 4,5 mg rivastigmiini rivastigmiinvesiniktartraadina.
English: Prometax 4.6 mg/24 h transdermal patch
Estonian: Prometax 4,6 mg/24 h transdermaalne plaaster
English: Each patch is sealed in a sachet that protects it until you are ready to put it on. Do not open the sachet or remove a patch until just before you apply it.
Estonian: Iga plaaster on suletud kotikesse, mis kaitseb seda kuni kasutamiseni.
English: Prometax 4.6 mg/24 h transdermal patch rivastigmine
Estonian: Prometax 4,6 mg/24 h transdermaalne plaaster Rivastigminum
English: Overdose with Prometax transdermal patch resulting from misuse/dosing errors (application of multiple patches at a time) has been reported in the post-marketing setting and rarely in clinical trials.
Estonian: Turuletulekujärgselt ja harva kliinilistes uuringutes on teatatud Prometax transdermaalsete plaastrite ebaõigest kasutamisest/annustamisvigadest (mitme plaastri samaaegne kasutamine) tingitud üleannustamisest.
English: Prometax 1.5 mg hard capsules rivastigmine
Estonian: Prometax 1,5 mg kõvakapslid Rivastigminum
English: Prometax 9.5 mg/24 h transdermal patch rivastigmine
Estonian: Prometax 9,5 mg/24 h transdermaalne plaaster Rivastigminum
English: 1 capsule contains 3.0 mg rivastigmine present as rivastigmine hydrogen tartrate.
Estonian: 1 kapsel sisaldab 3,0 mg rivastigmiini rivastigmiinvesiniktartraadina.
English: Headache, syncope, dizziness
Estonian: Peavalu, minestus, pearinglus
English: Prometax 3.0 mg hard capsules rivastigmine
Estonian: Prometax 3,0 mg kõvakapslid Rivastigminum
English: Keep the patch in the sachet until use.
Estonian: Kuni kasutamiseni hoida plaaster kotikeses.
English: Sodium benzoate Citric acid
Estonian: Naatriumbensoaat Sidrunhape
English: Each capsule contains rivastigmine hydrogen tartrate corresponding to 1.5 mg rivastigmine.
Estonian: Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 1,5 mg rivastigmiinile (Rivastigminum).
English: The patient's weight should be monitored during therapy with Prometax transdermal patches.
Estonian: Ravi ajal Prometax transdermaalsete plaastritega tuleb jälgida patsiendi kehakaalu.
English: Off-white to slightly yellow powder in a capsule with yellow cap and yellow body, with red imprint “ENA 713 1,5 mg” on body.
Estonian: Kapsli alaosale on punaselt trükitud “ENA 713 1,5 mg”.
English: • Push the nozzle of the syringe into the hole in the white stopper.
Estonian: Süstla viimine pudelisse • Asetage süstla ots valge aluskorgi avasse.
English: Prometax 13.3 mg/24 h transdermal patch rivastigmine
Estonian: Prometax 13,3 mg/24 h transdermaalne plaaster Rivastigminum
English: Off-white to slightly yellow powder in a capsule with red cap and orange body, with red imprint “ENA 713 6 mg” on body.
Estonian: Kapsli alaosale on punaselt trükitud “ENA 713 6 mg”.
English: Treatment should be temporarily interrupted if gastrointestinal adverse reactions are observed until these adverse reactions resolve.
Estonian: Kui tekivad seedetrakti kõrvaltoimed, tuleb ravi ajutiselt katkestada kuni kõrvaltoimete taandumiseni.
English: • Increased sweating
Estonian: • rohkenenud higistamine
English: Transdermal patches
Estonian: Transdermaalsed plaastrid
English: Each capsule contains rivastigmine hydrogen tartrate corresponding to 3.0 mg rivastigmine.
Estonian: Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 3,0 mg rivastigmiinile (Rivastigminum).
English: Each capsule contains rivastigmine hydrogen tartrate corresponding to 4.5 mg rivastigmine.
Estonian: Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 4,5 mg rivastigmiinile (Rivastigminum).
English: Renal and hepatic impairment
Estonian: Ravimit sisaldav kiht
English: Off-white to slightly yellow powder in a capsule with red cap and red body, with white imprint “ENA 713 4,5 mg” on body.
Estonian: Kapsli alaosale on valgelt trükitud “ENA 713 4,5 mg”.
English: Nausea
Estonian: Nahaärritus
English: ADCS-CGIC Placebo
Estonian: ADCSCGIC Platseebo
English: Prometax 9.5 mg/24 h transdermal patch
Estonian: Prometax 9,5 mg/24 h transdermaalne plaaster
English: Patients with clinically significant response (%)
Estonian: Kliiniliselt olulise ravivastusega patsiendid
English: Prometax 13.3 mg/24 h transdermal patch
Estonian: Prometax 13,3 mg/24 h transdermaalne plaaster
English: Prometax 1.5 mg hard capsules
Estonian: Prometax 1,5 mg kõvakapslid
English: Abdominal pain and dyspepsia
Estonian: Kõhuvalu ja düspepsia
English: EU/1/98/092/025 60 transdermal patches (sachet: paper/PET/alu/PAN) EU/1/98/092/026 90 transdermal patches (sachet: paper/PET/alu/PAN) EU/1/98/092/037 60 transdermal patches (sachet: paper/PET/PE/alu/PA) EU/1/98/092/038 90 transdermal patches (sachet: paper/PET/PE/alu/PA)
Estonian: EU/1/98/092/025 60 transdermaalset plaastrit (kotike: paber/PET/alu/PAN) EU/1/98/092/026 90 transdermaalset plaastrit (kotike: paber/PET/alu/PAN) EU/1/98/092/037 60 transdermaalset plaastrit (kotike: paber/PET/PE/alu/PA) EU/1/98/092/038 90 transdermaalset plaastrit (kotike: paber/PET/PE/alu/PA)
English: EU/1/98/092/029 60 transdermal patches (sachet: paper/PET/alu/PAN) EU/1/98/092/030 90 transdermal patches (sachet: paper/PET/alu/PAN) EU/1/98/092/041 60 transdermal patches (sachet: paper/PET/PE/alu/PA) EU/1/98/092/042 90 transdermal patches (sachet: paper/PET/PE/alu/PA)
Estonian: EU/1/98/092/029 60 transdermaalset plaastrit (kotike: paber/PET/alu/PAN) EU/1/98/092/030 90 transdermaalset plaastrit (kotike: paber/PET/alu/PAN) EU/1/98/092/041 60 transdermaalset plaastrit (kotike: paber/PET/PE/alu/PA) EU/1/98/092/042 90 transdermaalset plaastrit (kotike: paber/PET/PE/alu/PA)
English: Medicinal product matrix
Estonian: Ravimit vabastav sisekiht